← All trials
NCT06102044
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- Jun 1, 2026
- Completion date
- Jun 1, 2026
- First posted
- Oct 26, 2023
- Last posted
- Oct 26, 2023
- Enrollment
- 3250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Muhimbili UniversityCollaborator
- Muhimbili UniversityOverall official - principal investigator
- Muhimbili UniversityOfficial
- Harvard UniversityOfficial
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.